How IU Health leads the way in testicular cancer care

Watch the video to discover more about testicular cancer expertise at IU Health. Hear from our highly skilled physicians about what sets IU Health apart for testicular cancer care.

Testicular cancer is rare—it makes up only about 1% of all cancers in men. Even though it’s uncommon, it mostly affects young men in their 20s and 30s. That’s why effective treatment and long-term survival are so important. At IU Health, we’ve spent more than 60 years developing treatments that have changed testicular cancer care worldwide.

A Legacy of Innovation

Years ago, testicular cancer that had spread was often deadly. IU Health helped change that. Our doctors were among the first to develop a powerful treatment called cisplatin-based chemotherapy. This breakthrough greatly improved survival rates. By lowering side effects, combining cisplatin with other medicines, and adding surgery when needed, IU Health helped make testicular cancer one of the most curable cancers today.

Why Choose IU Health?

Experience matters—especially with a rare cancer like this. IU Health is recognized across the country and the world for leading testicular cancer treatment. Here’s what makes us stand out:

• Expert teams: Specialists in cancer care, urology, and other areas work together to give patients the best treatment with fewer side effects.
• Personalized care: Every patient gets a treatment plan designed just for them.
• Access to new treatments: IU Health leads research and clinical trials for new therapies, including targeted drugs, immunotherapy, and surgical trials. These studies aim to improve cure rates and reduce long-term side effects.

Survival Rates That Set the Standard

Thanks to IU Health’s work, about 80% of patients with advanced cancer are cured with first-line cisplatin chemotherapy. If the cancer comes back, IU Health offers high-dose chemotherapy with stem cell transplant—a treatment developed at IU Health. This cures about 60% of patients whose cancer returns.

Surgery as an Option

IU Health also leads in surgery for testicular cancer. For some patients, a procedure called retroperitoneal lymph node dissection (RPLND) can cure up to 80% of cases without chemotherapy. Additionally, RPLND surgery can be needed following chemotherapy – these surgeries are complex and require great skill—another reason IU Health is the best place for care.

Our Promise

Behind these advances is a team of doctors, nurses, and staff who guide patients from diagnosis to recovery. Our mission is simple: to give every patient the best chance at a healthy life. Cure rates are high, but we won’t stop until no one dies from testicular cancer.

Bottom line: If you or someone you know has testicular cancer, choose the center that sets the global standard for care. At IU Health, our experience, innovation, and commitment make us the best place for treatment.